SecBot SecBot

WHWK

Whitehawk Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001422142 Biotech & Drug Discovery
$3.14 −0.07 (−2.18%)
Oct 26 4:00 PM ET · prev $3.21
Market cap
$185.3M
Micro cap
Consensus
Buy
73% Buy or better · 15 analysts
Median target
$8.00
+155% · range $4.00–10.00
Next earnings
Nov 4
in 8 days · EPS est. −$0.24
1 year
+29.8%
from $2.42 · Oct 27
30 days
−16.5%
from $3.76
52-week range
$1.99–5.10
−38% from high · low Nov 20
Avg volume 20D
331.5K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$2.6M
0 buyers · 3 sellers · since Mar 1
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 4, 2026
Strongest NEUTRAL Whitehawk Therapeutics appointed Vijay Iyengar, M.D., a former Incyte executive, to its board of directors…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $2.6M.

  • InstitutionsBULLISH

    Q2 2026: 15 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    11 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.287 → −$0.237 over 90 days. 2 up, 0 down in 30 days.

  • TrendDOWNTREND

    21% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,922,828$8.8M
GEODE CAPITAL MANAGEMENT, LLCADD899,780$4.1M
Woodline Partners LPADD436,614$2.0M
STATE STREET CORPDOUBLED386,982$1.8M
BALYASNY ASSET MANAGEMENT L.P.TRIM288,117$1.3M
NORTHERN TRUST CORPDOUBLED264,689$1.2M
GOLDMAN SACHS GROUP INCDOUBLED126,758$580.6K
Point72 Asset Management, L.P.DOUBLED57,129$261.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 73% rate it Buy or better
Strong Buy5Buy6Hold4Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +155%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 1, 2026Stifel
INITIATE
INITIATEBuy
Jul 13, 2026Leerink Partners
INITIATE
INITIATEOutperform
Jun 25, 2026B. Riley Securities
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.6M
sold · 3 insiders
DateInsiderTypeValue
Sep 15, 2026
Dugan Margaret
Chief Medical Officer
AWARD81,250 sh
Sep 15, 2026
Lennon David James
CHIEF EXECUTIVE OFFICER
AWARD193,957 sh
Sep 15, 2026
Dugan Margaret
Chief Medical Officer
AWARD81,250 sh
Sep 15, 2026
Dornan David
Chief Scientific Officer
AWARD85,887 sh
Sep 15, 2026
Dornan David
Chief Scientific Officer
AWARD85,887 sh
Sep 15, 2026
BALL BRYAN
See remarks
AWARD91,633 sh
Sep 15, 2026
Lennon David James
CHIEF EXECUTIVE OFFICER
AWARD193,957 sh
Sep 15, 2026
BALL BRYAN
See remarks
AWARD91,633 sh

Earnings setup

Estimates
Nov 4
reports in 8 days
−$0.24
EPS estimate, this quarter
+17%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.24-$0.27–-$0.21+3.7%$0.00
Next Q-$0.24-$0.27–-$0.18-3.3%$0.00
Current FY-$0.97-$1.03–-$0.90-0.5%$0.00
Next FY-$0.99-$1.06–-$0.85-0.1%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 15, 2026 Insider
Dugan Margaret was granted 81,250 shares
Chief Medical Officer
Sep 15, 2026 Insider
Lennon David James was granted 193,957 shares
CHIEF EXECUTIVE OFFICER
Sep 15, 2026 Insider
Dugan Margaret was granted 81,250 shares
Chief Medical Officer
Sep 10, 2026 SEC
Whitehawk Therapeutics appointed Vijay Iyengar, M.D., a former Incyte executive, to its board of directors, filling a…
8-K — Impact 3/10
Aug 31, 2026 Short interest report
Short Interest: WHWK down 41% to 3.0M shares
Settlement 2026-08-31 | Days to cover: 12.51 | ≈5.23% of shares outstanding (est.)
Aug 6, 2026 SEC
Whitehawk Therapeutics reported Q2 2026 results with a net loss of $16.6M ($-0.20 EPS), narrower than the $52.6M loss…
8-K — Impact 3/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,922,828 shares ($8.8M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
899,780 shares ($4.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
WHWK Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Aug 31, 2026
Short interest
Short Interest: WHWK down 41% to 3.0M shares
Settlement 2026-08-31 | Days to cover: 12.51 | ≈5.23% of shares outstanding (est.)
Aug 14, 2026
Short interest
Short Interest: WHWK up 14% to 5.0M shares
Settlement 2026-08-14 | Days to cover: 10.42 | ≈8.83% of shares outstanding (est.)
Aug 5, 2026
Earnings date
WHWK Q2 2026 Earnings Scheduled — 2026-08-05
Jul 31, 2026
Short interest
Short Interest: WHWK up 6% to 4.4M shares
Settlement 2026-07-31 | Days to cover: 10.35 | ≈7.77% of shares outstanding (est.)
Jul 15, 2026
Short interest
Short Interest: WHWK up 48% to 4.2M shares
Settlement 2026-07-15 | Days to cover: 7.57 | ≈7.77% of shares outstanding (est.)

SecBot reports

10 filings · 0 bullish · 6 bearish · 4 neutral
All WHWK filing & press-release reports (10)